BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
58 hedge funds and large institutions have $14.1M invested in BRAINSTORM CELL THERAPUTC in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
21% more funds holding
Funds holding: 48 → 58 (+10)
11% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $1.45M
0.02% more ownership
Funds ownership: 1.16% → 1.18% (+0.02%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
31% less capital invested
Capital invested by funds: $20.4M → $14.1M (-$6.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.5M |
| 2 |
Renaissance Technologies
New York
|
+$571K |
| 3 |
Millennium Management
New York
|
+$349K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$287K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.07M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$507K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$507K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$450K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$113K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DJSG
51
D.J. St. Germain
Springfield,
Massachusetts
| $1.03K | +$1.37K | +33 | New |
|
52
BNP Paribas Financial Markets
Paris,
France
| $750 | – | – | – |
|
|
WIM
53
Westside Investment Management
Santa Monica,
California
| $412 | – | – | – |
|
|
MSFP
54
Mark Sheptoff Financial Planning
Glastonbury,
Connecticut
| $206 | – | – | – |
|
|
PFG
55
Piershale Financial Group
Barrington,
Illinois
| $206 | – | – | – |
|
|
NC
56
NewSquare Capital
Newtown Square,
Pennsylvania
| $144 | – | – | – |
|
57
JP Morgan Chase
New York
| $21 | -$8.21K | -198 | -99% |
|
|
58
Simplex Trading
Chicago,
Illinois
| – | -$507K | -12,226 | Closed |
|
|
59
Group One Trading
Chicago,
Illinois
| – | -$450K | -10,850 | Closed |
|
|
XT
60
XTX Topco
George Town,
Cayman Islands
| – | -$40.3K | -815 | Closed |
|
|
RJFSA
61
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$37.1K | -750 | Closed |
|
62
Fidelity Investments
Boston,
Massachusetts
| – | -$1.32K | -27 | Closed |
|
BCLI Hedge Fund Activity: Q2 2023 in Review
58 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2023, worth a combined $14.1M — down 31% from $20.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BCLI positions and 5 closed out — a net gain of 11 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $3.5M. The largest seller was AIGH Capital Management, cutting an estimated $2.07M.
- 58 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2023, up from 48 in Q1 2023.
- Funds reported $14.1M of BRAINSTORM CELL THERAPUTC stock for Q2 2023, down 31% quarter-over-quarter.
- 16 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2023 and 5 closed out, a net change of +11 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2023 was Sabby Management, an estimated $3.5M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2023 was AIGH Capital Management, an estimated $2.07M sold.
Based on aggregated 13F filings for Q2 2023.